Victoria Johnson

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

Recommendations have been largely preserved since 2018 and the USPSTF acknowledged the need for more research and better risk assessment tools.

However, gout flare states of patient acceptable symptom state, low disease activity, or not achieving either were not associated with EQ-5D-3L or HAQ.

Investigators found an incidence of 26.2 severe infections per 100 patient-years with 4 deaths in the study.

Small molecule drugs may help fill gaps in treatment with biologic therapies.

Tocilizumab and other biological drugs were particularly efficacious in lowering overall hemostatic potential, mitigating blood clot risks.

Around 37% of those had never used a bDMARD reached sustained DMARD-free remission at 5 years,

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.

CT-P42 may help improve access to aflibercept in lower-income countries.

Despite improvements in PROs and disease activity, no statistically significant changes have been seen on blood biomarker analysis.

The rheumatology month in review emphasizes new research in PsA and on cardiovascular events in rheumatic disease.

An active comparator study found that incident use of gabapentin was associated with lower rates of falls than duloxetine and similar rates of severe falls.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Other recent research presented at ACR 2024 found increased CVD risk with glucocorticosteroid use.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

This year in review spotlights top rheumatology FDA news from 2024 and new research out of the ACR 2024 Convergence.

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.

The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.

These findings, from an observational study, should be confirmed in a randomized, controlled trial.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.